Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema

Inclusion Criteria: * Male or female, 18 years of age or older. * Study eye with clinically significant diabetic macular edema (DME) with central subfield thickness ≥ 350µm on spectral domain OCT * Best corrected visual acuity (BCVA) of 20/50 to 20/320 ETDRS equivalent (65 letters to 23 letters) in the study eye, with BCVA decrement primarily attributable to DME. * Treatment naïve, i.e., no previous anti-VEGF treatment in the study eye or no anti-VEGF treatment in the 45 days prior to study enrollment. * In the investigator's opinion, the subject still has significant intraretinal fluid with room for improvement in both macular edema and BCVA. * Intra-Ocular Pressure (IOP) is under control (i.e., IOP ≤ 25 mm in the study eye) and study eye is not receiving any IOP lowering drops. * Willing and able to return for all study visits. * Able to meet the extensive post-op evaluation regimen. * Understands and signs the informed consent form. Exclusion Criteria: * Active proliferative diabetic retinopathy (PDR) in the study eye such as NVE, NVD, vitreous hemorrhage, or neovascular glaucoma. * Uncontrolled hypertension defined as systolic \>180 mmHg or \> 160 mmHg on 2 consecutive measurements or diastolic \> 100 mmHg on optimal medical regimen * Screening HgA1c blood test \> 10.0 * Focal laser photocoagulation or intravitreal/periocular steroids of any type in the study eye within the last 90 days prior to study enrollment. * A history of intravitreal anti-VEGF injection of any type in the study eye within the last 45 days prior to study enrollment. * History of rhegmatogenous retinal detachment, retinal tear(s), or traction retinal detachments in the study eye. * Epiretinal membrane and/or vitreomacular traction in the study eye as determined by the central reading center. * Previous pars plana vitrectomy in the study eye * Any intraocular surgery in the study eye within the last 90 days prior to study enrollment. * YAG laser treatment in the study eye in last 30 days prior to study enrollment. * High myopia in the study eye, with a spherical equivalent of \>8.00D at screening * Other ocular pathologies that in the investigator's opinion would interfere with the subject's vision in the study eye. * Chronic or recurrent uveitis. * Ongoing ocular infection or inflammation in either eye. * A history of cataract surgery complications/vitreous loss in the study eye. * Congenital eye malformations in the study eye. * A history of penetrating ocular trauma in the study eye. * Mentally handicapped. * Pregnant female, as determined for women less than 60 years old by a positive urine pregnancy test during the screening window. * Nursing female. * Currently participating in any other clinical research study. * Contraindication to the study medication.